CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oakley-Girvan, I.
Right arrow Articles by Whittemore, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oakley-Girvan, I.
Right arrow Articles by Whittemore, A. S.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 1325-1330, August 2004
© 2004 American Association for Cancer Research

Risk of Early-Onset Prostate Cancer in Relation to Germ Line Polymorphisms of the Vitamin D Receptor

Ingrid Oakley-Girvan1, David Feldman2, T. Ross Eccleshall2, Richard P. Gallagher3, Anna H. Wu4, Laurence N. Kolonel5, Jerry Halpern1, Raymond R. Balise1, Dee W. West6, Ralph S. Paffenbarger, Jr.1 and Alice S. Whittemore1

Departments of 1 Health Research and Policy and 2 Medicine-Endocrinology, Stanford University School of Medicine, Stanford, California; 3 Division of Epidemiology, Biometry and Occupational Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; 4 Department of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; 5 Cancer Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii; and 6 Northern California Cancer Center, Union City, California

Requests for reprints: Alice S. Whittemore, Department of Health Research and Policy, Stanford University School of Medicine, HRP Redwood Building, T204, Stanford, CA 94305-5405. Phone: 650-723-5460; Fax: 650-725-6951. E-mail: alicesw{at}stanford.edu

Vitamin D inhibits prostate cancer cell growth, angiogenesis, and metastasis. These actions are mediated by the vitamin D receptor. We examined associations between prostate cancer risk and five polymorphisms in the VDR gene: four single nucleotide polymorphisms (FokI, BsmI, ApaI, and TaqI restriction sites) and the polyadenylic acid microsatellite. Specifically, we genotyped population-based samples of young African Americans (113 cases and 121 controls) and Whites (232 cases and 171 controls) and members of 98 predominantly White families with multiple cases of prostate cancer. Among Whites, there was no evidence for association between prostate cancer risk and alleles at any of the five polymorphic sites regardless of how the men were ascertained. Moreover, estimated five-locus haplotype frequencies were similar in White cases and controls. Among African Americans, prostate cancer risk was associated with homozygosity for the F allele at the FokI site (odds ratio 1.9, 95% confidence interval 1.0-3.3). In addition, estimated haplotype frequencies differed significantly (P < 0.01) between African American cases and controls. These findings need replication in other studies of African Americans. Homozygosity for the F allele at the FokI site is more prevalent in the African American population than in U.S. Whites. If the FokI association noted here were causal, this difference could account for some of the disease burden among African Americans and some of the excess risk in African Americans compared with Whites.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. J. Borugian, J. J. Spinelli, Z. Sun, L. N. Kolonel, I. Oakley-Girvan, M. D. Pollak, A. S. Whittemore, A. H. Wu, and R. P. Gallagher
Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 252 - 254.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Hirata, Y. Hinoda, N. Kikuno, K. Kawamoto, A. V. Dahiya, Y. Suehiro, Y. Tanaka, and R. Dahiya
CXCL12 G801A Polymorphism Is a Risk Factor for Sporadic Prostate Cancer Susceptibility
Clin. Cancer Res., September 1, 2007; 13(17): 5056 - 5062.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. S. Cicek, X. Liu, F. R. Schumacher, G. Casey, and J. S. Witte
Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2549 - 2552.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
R A Kittles, A B Baffoe-Bonnie, T Y Moses, C M Robbins, C Ahaghotu, P Huusko, C Pettaway, S Vijayakumar, J Bennett, G Hoke, et al.
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history
J. Med. Genet., June 1, 2006; 43(6): 507 - 511.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles
Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer
Cancer Res., June 15, 2005; 65(12): 5470 - 5479.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.